Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a sell rating to a hold rating in a report issued on Friday morning.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

Several other equities analysts also recently weighed in on the company. Jefferies Group reiterated a buy rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. ValuEngine upgraded Kamada from a sell rating to a hold rating in a research report on Friday, January 5th. Chardan Capital initiated coverage on Kamada in a research report on Friday, February 2nd. They set a buy rating and a $7.00 target price on the stock. Finally, HC Wainwright reiterated a buy rating on shares of Kamada in a research report on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $7.00.

Kamada (NASDAQ KMDA) opened at $5.00 on Friday. The firm has a market capitalization of $201.31, a price-to-earnings ratio of 29.41 and a beta of 1.14. The company has a current ratio of 3.30, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.10. The company had revenue of $35.71 million for the quarter, compared to the consensus estimate of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. equities analysts anticipate that Kamada will post 0.21 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC purchased a new position in Kamada during the fourth quarter valued at $251,000. Jane Street Group LLC purchased a new position in shares of Kamada in the third quarter valued at about $112,000. Analyst IMS Investment Management Services Ltd. lifted its position in shares of Kamada by 125.5% in the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares in the last quarter. Worth Venture Partners LLC purchased a new position in shares of Kamada in the third quarter valued at about $246,000. Finally, Paulson & CO. Inc. lifted its position in shares of Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after acquiring an additional 60,000 shares in the last quarter. Institutional investors own 6.26% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/13/kamada-kmda-upgraded-at-zacks-investment-research.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.